Adma Biologics reported $57.13M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Adma Biologics USD 57.13M 4.47M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Novavax USD 17.9M 220.94M Dec/2025
Omeros USD -65.12M 21.27M Jun/2024
Takeda JPY -52.48B 186.34B Mar/2026